公开(公告)号：AU5958298A

公开(公告)日：1998-08-03

申请号：AU5958298

申请日：1998-01-07

Applicant: ABBOTT LAB

Inventor： DAVIDSEN STEVEN K ,  FLORJANCIC ALAN SCOTT ,  SHEPPARD GEORGE S ,  GIESLER JAMIE R ,  XU LIANHONG ,  GUO YAN ,  CURTIN MICHAEL L ,  MICHAELIDES MICHAEL R ,  WADA CAROL K ,  HOLMS JAMES H

IPC: A61K31/165 ,  A61K31/197 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/426 ,  A61K31/4406 ,  A61P19/02 ,  A61P19/10 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07C233/32 ,  C07C259/06 ,  C07D207/32 ,  C07D207/323 ,  C07D207/335 ,  C07D209/14 ,  C07D213/50 ,  C07D235/14 ,  C07D263/32 ,  C07D277/24 ,  C07D277/28 ,  C07D277/30 ,  C07D333/22 ,  C07D209/18 ,  A61K31/38 ,  A61K31/40 ,  A61K31/42 ,  A61K31/44 ,  C07D207/337 ,  C07D213/56 ,  C07D235/16 ,  C07D333/24

公开(公告)号：CA2277105A1

公开(公告)日：1998-07-16

申请号：CA2277105

申请日：1998-01-07

Applicant: ABBOTT LAB

Inventor： GIESLER JAMIE R ,  SHEPPARD GEORGE S ,  XU LIANHONG ,  FLORJANCIC ALAN SCOTT ,  HOLMS JAMES H ,  WADA CAROL K ,  GUO YAN ,  DAVIDSEN STEVEN K ,  CURTIN MICHAEL L ,  MICHAELIDES MICHAEL R

IPC: A61K31/165 ,  A61K31/197 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/426 ,  A61K31/4406 ,  A61P19/02 ,  A61P19/10 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07C233/32 ,  C07C259/06 ,  C07D207/32 ,  C07D207/323 ,  C07D207/335 ,  C07D209/14 ,  C07D213/50 ,  C07D235/14 ,  C07D263/32 ,  C07D277/24 ,  C07D277/28 ,  C07D277/30 ,  C07D333/22 ,  C07D209/18 ,  A61K31/38 ,  A61K31/40 ,  A61K31/42 ,  A61K31/44 ,  C07D207/337 ,  C07D213/56 ,  C07D235/16 ,  C07D333/24

Abstract: C-terminal compounds of formula (I) are potent inhibitors of matrix metalloproteinase and are useful in the treatment of diseases in which matrix metalloproteinase play a role. Also disclosed are matrix metalloproteinase inhibiting compositions and a method of inhibiting matrix metalloproteinase in a mammal.

公开(公告)号：AU7729696A

公开(公告)日：1997-06-05

申请号：AU7729696

申请日：1996-11-13

Applicant: ABBOTT LAB

Inventor： FESIK STEPHEN W ,  SUMMERS JAMES B JR ,  DAVIDSEN STEVEN K ,  SHEPPARD GEORGE S ,  STEINMAN DOUGLAS H ,  CARRERA GEORGE M JR ,  FLORJANCIC ALAN ,  HOLMS JAMES H

IPC: A61P19/02 ,  A61K31/185 ,  A61K31/275 ,  A61P29/00 ,  A61P35/04 ,  A61P43/00 ,  C07C259/06 ,  C07C323/60 ,  A61K31/16

Abstract: Compounds of formula or a pharmaceutically acceptable salt thereof inhibit matrix metalloproteinases and TNF alpha secretion and are useful in the treatment of inflammatory disease states. Also disclosed are matrix metalloproteinases and TNF alpha secretion inhibiting compositions and a method for inhibiting matrix metalloproteinases and TNF alpha secretion.

公开(公告)号：AU5181590A

公开(公告)日：1990-09-26

申请号：AU5181590

申请日：1990-02-06

Applicant: ABBOTT LAB

Inventor： BROOKS DEE W ,  KERDESKY FRANCIS A J ,  HOLMS JAMES H

IPC: C07D277/20 ,  A61K31/425 ,  A61K31/426 ,  A61K31/44 ,  A61P1/00 ,  A61P11/00 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07D277/34 ,  C07D277/54 ,  C07D277/64 ,  C07D417/04 ,  C07D233/32

Abstract: A composition for the inhibition of lipoxygenase enzymes comprising a pharmaceutically acceptable carrier and a compound of the formula: I wherein R1 and R2 are independently selected from the group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, arylalkenyl, reduced heteroaryl, and reduced heteroarylalkyl and substituted derivatives thereof having one or more substituents independently selected from the group consisting of halogen, alkyl, halosubstituted alkyl, aryl, arylalkyl, reduced heteroaryl, arylalkoxy, cyano, nitro, COR4, SO2R4, NR5R6, OR6, COCX1X2NR6R7, CON(OH)R6, NR6COR4, CR5(NH2)CO2R5, NHCX1X2CO2R5, N(OH)CONR5R6, N(OH)COR4, NHCONR5R6, C(NOH)NHOH and CONHNR5R6; R3 is selected from the group consisting of hydrogen, a pharmaceutically acceptable salt, COR4, COCX1X2NR6R7, CR8R9OR10, CH2CR8(OR10)CH2OR11 and SiR12R13R14; R4 is selected from the group consisting of hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced heteroaryl, reduced heteroarylalkyl, OR5, NHCX1X2CO2R5 and NR6R7; R5 is selected from the group consisting of hydrogen, alkyl, alkenyl, cycloalkyl, aryl, arylalkyl, reduced heteroaryl, and reduced heteroarylalkyl; R6 and R7 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, cycloalkyl, aryl, arylalkyl, reduced heteroaryl, reduced heteroarylalkyl and (CH2)nOR5 where n is 2-4 and R5 is as defined above; R8, R9, R10 and R11 are independently selected from the group consisting of hydrogen, alkyl, aryl, arylalkyl and (CH2)nOR5 or at least two of R8, R9, R10 and R11 together form a ring system containing 5-10 atoms wherein said ring system is carbocyclic, heterocyclic or reduced heterocyclic and R5 and n are as defined above; R12, R13 and R14 are independently selected from the group consisting of alkyl and aryl; and X1 and X2 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, cycloalkyl, aryl, and arylalkyl; and the acid addition salts thereof.